Clinical Trial Update: Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

This updates a Phase II neoadjuvant trial of dasatinib in early-stage non-small cell lung cancer; the study was terminated and results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Sprycel (dasatinib)

Snippet

Sponsor: Duke University | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: TERMINATED | Results posted: 2013-03-08